Further, the co-expression of KLF9 and KLF13 transcripts is evident in the tumor-associated immune cells (e.g., B cells, mast cells, myeloid cells, and T cells), whereas KLF13 mRNA predominates in the tumor-associated plasma cells. This evidence concerns the gene KLF9 and neoplasm.